美康生物(300439) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥493,826,953.07, a decrease of 19.11% compared to the same period last year[3]. - Net profit attributable to shareholders was ¥55,090,894.33, down 3.17% year-on-year, while net profit excluding non-recurring items was ¥44,434,317.38, a decrease of 21.82%[3]. - In the first three quarters of 2023, the company achieved operating revenue of CNY 1,470.63 million, a decrease of 22.65% year-on-year[15]. - The net profit attributable to shareholders of the listed company was CNY 229.96 million, an increase of 13.03% year-on-year[15]. - Total revenue for Q3 2023 was CNY 1,470,634,733, a decrease of 22.7% compared to CNY 1,901,219,803 in Q3 2022[24]. - Net profit for Q3 2023 reached CNY 223,644,277.20, an increase of 12.1% from CNY 199,556,848.25 in Q3 2022[24]. - The total comprehensive income attributable to the parent company for Q3 2023 was CNY 229,750,522.90, an increase from CNY 200,495,065.67 in the same period last year, representing a growth of approximately 14.5%[25]. Cash Flow and Assets - The operating cash flow net amount for the year-to-date period reached ¥373,776,026.11, reflecting a significant increase of 68.67%[3]. - Cash flow from investment activities showed a net outflow of ¥86,074,129.29, an improvement of 30.32% compared to the previous year[12]. - The company's cash and cash equivalents increased to CNY 929,317,475.80 as of September 30, 2023, compared to CNY 806,412,812.69 at the beginning of the year, representing a growth of 15.2%[22]. - The total cash inflow from operating activities decreased to CNY 1,776,454,531.28 in Q3 2023 from CNY 1,985,001,810.12 in Q3 2022, reflecting a decline of approximately 10.5%[26]. - The cash outflow from investing activities for Q3 2023 was CNY 384,439,610.80, up from CNY 355,286,628.20 in the previous year, marking an increase of about 8.2%[27]. - The total assets at the end of the reporting period were ¥3,561,742,708.69, a slight decrease of 0.61% from the previous year-end[3]. - The total liabilities decreased to CNY 883,775,250.67 from CNY 1,064,233,390.98, a decline of 16.9%[22]. Shareholder and Equity Information - The company's equity attributable to shareholders increased by 7.50% year-on-year, reaching ¥2,698,361,122.49[3]. - The total number of common stock shareholders at the end of the reporting period was 31,324[14]. - The controlling shareholder, Zou Bingde, committed not to reduce his shareholding in the company for six months from September 21, 2023[18]. - The company’s equity attributable to shareholders increased to CNY 2,698,361,122.49 from CNY 2,510,065,477.78, reflecting a growth of 7.5%[22]. Research and Development - The company continues to invest in R&D to enrich its self-produced product categories, laying a foundation for future sales[16]. - The company launched five new products in the chemiluminescence field, including a soluble fms-like tyrosine kinase-1 detection kit[16]. - The company is focusing on developing high-speed chemiluminescence analyzers and expanding its mass spectrometry product offerings[16]. - The company aims to support its self-produced product sales and medical diagnostic services through the development of mass spectrometry reagent products[16]. - Research and development expenses for Q3 2023 were CNY 118,629,648.80, slightly down from CNY 125,871,139.22 in Q3 2022[24]. Operating Costs - The company experienced a 31.13% decrease in operating costs, totaling ¥810,573,354.36, attributed to the decline in revenue[10]. - Total operating costs for Q3 2023 were CNY 1,270,149,197.62, down from CNY 1,663,730,307.37 in the same period last year, reflecting a reduction of 23.6%[24].